{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026815","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.026025+00:00","generated_at":"2026-05-31T09:17:40.095909+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Talphera Q2 net loss $3.8M; CMO Palmer retiring Oct 1, succeeded by Dr. Aslam","bullets":["Net loss $3.8M ($0.15 loss per share) vs $4.4M ($0.40 loss) in Q2 2023; cash $14.0M.","NEPHRO CRRT registrational study screening initiated; enrolling 166 patients at up to 14 U.S. sites.","Pamela Palmer, co-founder and CMO, to retire Oct 1; Dr. Shakil Aslam (current CDO) to become CMO.","Combined R&D and SG&A expenses rose to $4.3M from $4.2M year-over-year; no DSUVIA expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026815","json":"https://secwatch.observer/filing/0001437749-24-026815.json","markdown":"https://secwatch.observer/filing/0001437749-24-026815.md","text":"https://secwatch.observer/filing/0001437749-24-026815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/0001437749-24-026815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/acrx20240814_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:40.095909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b11649b19d","claim":"Shakil Aslam was appointed as Chief Medical Officer at TALPHERA, INC..","evidence_excerpt":"Upon Dr. Palmer’s retirement, Dr. Shakil Aslam, currently the Company’s Chief Development Officer, will assume the position of the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/0001437749-24-026815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"f97f5f84eb","claim":"Pamela P. Palmer resigned as Chief Medical Officer at TALPHERA, INC..","evidence_excerpt":"On August 12, 2024, Pamela P. Palmer, MD, PhD, the Company’s Chief Medical Officer and co-founder, notified the Company that she plans to retire and resign from the Company effective October 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/0001437749-24-026815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}